Thera-SAbDab

BAVITUXIMAB

>   Structural Summary
TherapeuticBavituximab
TargetPhosphatidylserine
Heavy ChainEVQLQQSGPELEKPGASVKLSCKASGYSFTGYNMNWVKQSHGKSLEWIGHIDPYYGDTSYNQKFRGKATLTVDKSSSTAYMQLKSLTSEDSAVYYCVKGGYYGHWYFDVWGAGTTVTVSS
Light ChainDIQMTQSPSSLSASLGERVSLTCRASQDIGSSLNWLQQGPDGTIKRLIYATSSLDSGVPKRFSGSRSGSDYSLTISSLESEDFVDYYCLQYVSSPPTFGAGTKLELK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-III
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2006
INN Year Recommended2007
Companies InvolvedAvid Bioservices, IMV, Massachusetts General Hospital, Merck Sharp & Dohme, Peregrine Pharmaceuticals, University of Arizona, University of Texas Southwestern Medical Center, University of Texas M. D. Anderson Cancer Center
Conditions Approvedna
Conditions ActiveNon-small cell lung cancer, Glioblastoma, Liver cancer, Solid tumours
Conditions DiscontinuedBreast cancer, Malignant melanoma, Pancreatic cancer, Brain cancer, Hepatitis C, HIV infections, Rectal cancer, Viral haemorrhagic fevers, Influenza virus infections, Prostate cancer
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]